Pathway Pharmaceuticals, a Hong Kong-based personalized medicine company that helps medical professionals make more informed decisions when selecting cancer therapies, received a seed funding from Deep Knowledge Ventures.
The amount of the deal was not disclosed.
Led by Anton Buzdin, PHD, DSC, CEO, Pathway Pharmaceuticals has just launched its service to medical professionals worldwide, which tests the effects of drugs that are approved by national regulatory agencies on gene expression in patient tumor biopsies. Its OncoFINDER™ tool uses advanced algorithms to predict drug efficacy by comparing the gene expression data of tumor biopsies to a large sample of data from healthy tissue collected over 7 years.
This information can also be used to analyze the efficacy of treatments currently in clinical trials and in the laboratory.
The company also has operations in the United States, Russia and the United Kingdom.